|Bid||183.79 x 1000|
|Ask||183.52 x 1200|
|Day's Range||180.83 - 184.53|
|52 Week Range||98.02 - 206.74|
|Beta (5Y Monthly)||1.32|
|PE Ratio (TTM)||49.45|
|Earnings Date||Oct 22, 2020 - Oct 26, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Mar 29, 1994|
|1y Target Est||228.47|
Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, and LabCorp (NYSE: LH), a leading global life sciences company, today announced a collaboration with LabCorp’s drug development business, Covance. LabCorp will participate in Tempus's TIME Trial® Network and the companies will work together to accelerate patient enrollment for oncology clinical trials through an innovative, data-driven approach that aims to transform the clinical trial model and modernize how they are designed and executed.
In the latest trading session, LabCorp (LH) closed at $183.13, marking a +0.91% move from the previous day.
<!DOCTYPE html> <html lang="" xml:lang=""> <head> <title>/nwsys/www/images/PBC_1244492</title> <meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/> <meta name="generator" content="pdftohtml 0.